Cellular Senescence, Insulin Resistance, and CDKN2B: An Intrinsic Connection in Metabolic Diseases
DOI:
https://doi.org/10.54097/37w03826Keywords:
Insulin Resistance, Cellular Senescence, Adipocyte Aging, CDKN2B, CDKN2B-AS, Type 2 Diabetes, SASP, Metabolic DiseasesAbstract
This review summarizes the pivotal roles of insulin resistance (IR) and cellular senescence in metabolic diseases, focusing on how adipocyte and hepatocyte senescence promote IR and the progression of type 2 diabetes through the senescence-associated secretory phenotype (SASP) and key signaling pathways (e.g., p53, Akt/FoxO1). The article further focuses on the cell cycle regulatory gene CDKN2B and its non-coding RNA (CDKN2B-AS), elucidating their expression alterations and genetic susceptibility in various metabolic diseases including atherosclerosis, coronary heart disease, polycystic ovary syndrome, and diabetes. Although the role of CDKN2B in aging and metabolic regulation remains unclear, existing evidence suggests it may exert complex and critical regulatory effects on the pathogenesis of metabolic diseases by influencing insulin resistance patterns and tissue-specific senescence phenotypes. Future research should further elucidate the functional differences of CDKN2B and its isoforms across various tissues and disease states.
Downloads
References
[1] Xing Xiaoyan, Yang Wenying, Yang Zhaojun. Role of the Insulin Resistance Index in Diagnosing Metabolic Syndrome Among Individuals with Different Glucose Tolerance Profiles. Chinese Journal of Diabetes. 2004; 12:182-6.
[2] Baker DJ, Jeganathan KB, Cameron JD, Thompson M, Juneja S, Kopecka A, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nature genetics. 2004; 36:744-9.
[3] Hernandez-Segura A, Nehme J, Demaria M. Hallmarks of Cellular Senescence. Trends in cell biology. 2018;28:436-53.
[4] Rhinn M, Ritschka B, Keyes WM. Cellular senescence in development, regeneration and disease. 2019;146.
[5] Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nature medicine. 2015;21:1424-35.
[6] Kursawe R, Dixit VD, Scherer PE, Santoro N, Narayan D, Gordillo R, et al. A Role of the Inflammasome in the Low Storage Capacity of the Abdominal Subcutaneous Adipose Tissue in Obese Adolescents. Diabetes. 2016;65:610-8.
[7] Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature immunology. 2011;12:408-15.
[8] Minamino T, Orimo M, Shimizu I, Kunieda T, Yokoyama M, Ito T, et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nature medicine. 2009; 15:1082-7.
[9] Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scrable H, et al. Fat tissue, aging, and cellular senescence. Aging cell. 2010;9:667-84.
[10] Ye J. Mechanism of insulin resistance in obesity: a role of ATP. Frontiers of medicine. 2021;15:372-82.
[11] Pérez LM, Pareja-Galeano H, Sanchis-Gomar F, Emanuele E, Lucia A, Gálvez BG. 'Adipaging': ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue. The Journal of physiology. 2016;594:3187-207.
[12] Sebo ZL, Rodeheffer MS. Assembling the adipose organ: adipocyte lineage segregation and adipogenesis in vivo. 2019; 146.
[13] Slawik M, Vidal-Puig AJ. Lipotoxicity, overnutrition and energy metabolism in aging. Ageing research reviews. 2006; 5: 144-64.
[14] Aravinthan A, Challis B, Shannon N, Hoare M, Heaney J, Alexander GJM. Selective insulin resistance in hepatocyte senescence. Experimental cell research. 2015;331:38-45.
[15] Li Q, Hagberg CE. Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce. 2021;27:1941-53.
[16] Burton DGA, Faragher RGA. Obesity and type-2 diabetes as inducers of premature cellular senescence and ageing. Biogerontology. 2018;19:447-59.
[17] Simboeck E, Ribeiro JD, Teichmann S, Di Croce L. Epigenetics and senescence: learning from the INK4-ARF locus. Biochemical pharmacology. 2011;82:1361-70.
[18] Kojima Y, Downing K, Kundu R, Miller C, Dewey F, Lancero H, et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. The Journal of clinical investigation. 2019;129:2164.
[19] Svensson PA, Wahlstrand B, Olsson M, Froguel P, Falchi M, Bergman RN, et al. CDKN2B expression and subcutaneous adipose tissue expandability: possible influence of the 9p21 atherosclerosis locus. Biochemical and biophysical research communications. 2014;446:1126-31.
[20] Zhou S, Cai B, Zhang Z, Zhang Y, Wang L, Liu K, et al. CDKN2B Methylation and Aortic Arch Calcification in Patients with Ischemic Stroke. Journal of atherosclerosis and thrombosis. 2017;24:609-20.
[21] Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ (Clinical research ed). 2006;332:73-8.
[22] Abdel-Maksoud MF, Eckel RH, Hamman RF, Hokanson JE. Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and non-high-density lipoprotein cholesterol in men. Journal of clinical lipidology. 2012;6:374-81.
[23] An P, Feitosa M, Ketkar S, Adelman A, Lin S, Borecki I, et al. Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study. BMC proceedings. 2009;3 Suppl 7:S71.
[24] Zhong J, Chen X, Ye H, Wu N, Chen X, Duan S. CDKN2A and CDKN2B methylation in coronary heart disease cases and controls. Experimental and therapeutic medicine. 2017;14: 6093-8.
[25] Ou M, Li X, Zhao S, Cui S, Tu J. Long non-coding RNA CDKN2B-AS1 contributes to atherosclerotic plaque formation by forming RNA-DNA triplex in the CDKN2B promoter. EBioMedicine. 2020;55:102694.
[26] Huang Y, Zhang Y, Zhou Y, Chen Y, Zhu Q. CDKN2B-AS1 is overexpressed in polycystic ovary syndrome and sponges miR-181a to promote granulosa cell proliferation. Anti-cancer drugs. 2023;34:207-13.
[27] Li H, Han S, Sun Q, Yao Y, Li S, Yuan C, et al. Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression. Aging. 2019;11:1695-715.
[28] Holdt LM, Hoffmann S, Sass K, Langenberger D, Scholz M, Krohn K, et al. Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS genetics. 2013;9:e1003588.
[29] Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS genetics. 2010;6:e1001233.
[30] Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. 2016;7:12429.
[31] Sarkar D, Oghabian A, Bodiyabadu PK, Joseph WR, Leung EY, Finlay GJ, et al. Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing. International journal of molecular sciences. 2017;18.
[32] Muniz L, Lazorthes S. Circular ANRIL isoforms switch from repressors to activators of p15/CDKN2B expression during RAF1 oncogene-induced senescence. 2021;18:404-20.
[33] Ma RC, Lin X, Jia W. Causes of type 2 diabetes in China. The lancet Diabetes & endocrinology. 2014;2:980-91.
[34] Rong R, Hanson RL, Ortiz D, Wiedrich C, Kobes S, Knowler WC, et al. Association analysis of variation in/near FTO, CDKAL1, SLC30A8, HHEX, EXT2, IGF2BP2, LOC387761, and CDKN2B with type 2 diabetes and related quantitative traits in Pima Indians. Diabetes. 2009;58:478-88.
[35] Horswell SD, Fryer LG, Hutchison CE, Zindrou D, Speedy HE, Town MM, et al. CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients. Journal of lipid research. 2013;54:3491-505.
[36] Ruchat SM, Elks CE, Loos RJ, Vohl MC, Weisnagel SJ, Rankinen T, et al. Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies. Acta diabetologica. 2009;46:217-26.
[37] Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B. Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. PLoS genetics. 2010;6:e1000899.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
